Insider buying last 90 days
No open-market insider purchases were filed for REGN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every REGN insider filing, plotted on the chart in Gekko.Open REGN in Gekko
NASDAQ: REGN
Regeneron Pharmaceuticals (REGN) Stock Analysis & Forecast
Nov 4 close
$930.67−42.69 (−4.4%)
Gekko Brief
AI summaryNov 4 closeRegeneron's week centers on a strong third-quarter report, with revenue growth of 36% and non-GAAP EPS growth of 70% year over year, marking a third straight quarter of double-digit growth. Dupixent global net sales reached a record $6.5 billion, up 35% in constant currency, with US sales topping $5 billion for the first time, while EYLEA HD US net sales grew 62% to roughly $700 million and Libtayo global sales rose 51% to $550 million. The company also affirmed its dividend, continued share buybacks, expanded its BARDA agreement for Ebola treatment, and presented additional data, even as shares fell 4.39% to $930.67 on a day when broader indexes advanced.
The stock closed at $930.67, above both its 50-day average of $800.69 and 200-day average of $740.82, with the shorter average above the longer one, reflecting an established uptrend despite the one-day decline of 4.4%. The GekkoIndex reads 38.2, placing REGN in the Distribution zone, down 12.7 points over five days. Price sits 28.3% below Gekko Fair Value of $1,298.15.
The next earnings date is 28 January 2027, 84 days out, beyond a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Analyst coverage includes 24 firms, with 16 at buy and 8 at hold, and a consensus target of $969.59, implying 4.2% upside. Seasonally, the next 20 trading days have averaged a 1.3% gain over 5 years, positive in 3 of them. The gap to Gekko Fair Value and the Distribution reading bear watching alongside typical daily swings near 3.4%.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Regeneron Pharmaceuticals price vs fair value
Close $930.67200-day averageGekko Fair Value $1,298.15
Regeneron Pharmaceuticals quick facts
- Market cap
- $95.80B
- P/E ratio
- 21.3
- Forward P/E
- 15.4
- EPS, TTM
- $45.24
- Revenue, TTM
- $16.90B
- Profit margin
- 28.5%
- Dividend yield
- 0.40%
- Beta
- 0.10
- Volume
- 1.38M avg 854,230
- 1-year return
- +44.9%
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±5%
- 50-day average
- $800.69
- 200-day average
- $740.82
- Next earnings
- Jan 28 before open
- Shares outstanding
- 101.6M
Regeneron Pharmaceuticals swing-trade checklist
Regeneron Pharmaceuticals scores 4 supportive, 0 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $930.67 is above the 50-day ($800.69) and 200-day ($740.82) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
38.2, Distribution
Reading 38.2 is in the Distribution zone.
See the GekkoIndex - Fair valuesupportive
28.3% below
Price is 28.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 84 days
Next report Jan 28, 2027, 84 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.3% on average
From this point in the calendar, the next 20 trading days averaged +1.3% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Regeneron Pharmaceuticals stock chart and price history
Regeneron Pharmaceuticals closed at $930.67 on Nov 4, 2026, +44.9% over the past year, inside a 52-week range of $591.52 to $991.73.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +26.0%
- 3 months
- +20.5%
- 6 months
- +29.1%
- 1 year
- +44.9%
The full REGN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open REGN in Gekko
Follow Regeneron Pharmaceuticals through every session
Put REGN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track REGN in GekkoFree for 7 days. No credit card required.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals develops medicines that treat serious health conditions, spanning eye disease, immune and allergic disorders, cancer, infectious disease and rare conditions. Its treatments reach patients through injectable and infused therapies for conditions such as macular degeneration, atopic dermatitis, asthma, skin cancer, high cholesterol, rheumatoid arthritis, Ebola infection and periodic fever syndromes, among others. The company is perhaps best recognized for its work in eye care and immune-related treatments, alongside its broader pipeline of experimental drugs still in development.
Much of its business runs through partnerships rather than solely independent efforts, with collaboration and licensing arrangements involving other pharmaceutical companies and research organizations, as well as government health bodies. These relationships support both the commercialization of approved treatments and ongoing research into new drug candidates across multiple disease areas.
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, New York. Its shares are listed on the NASDAQ under the ticker REGN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- regeneron.com
Regeneron Pharmaceuticals GekkoIndex: the smart money zone
Regeneron Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 38.2, in the Distribution zone, down 12.7 points over five sessions.
38.2Distribution
Down 12.7 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 66 | −1.1% | −4.3% | ||
| Accumulation | 209 | +0.1% | −1.4% | ||
| Neutral | 374 | +0.1% | +1.0% | ||
| Distribution (current zone) | 47 | +1.1% | +3.0% | ||
| Selling | 1 | Too few readings yet | |||
Average REGN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the REGN price, zone by zone.Track REGN in Gekko
Is Regeneron Pharmaceuticals stock overvalued? Gekko Fair Value
Regeneron Pharmaceuticals trades 28.3% below Gekko Fair Value of $1,298.15, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Regeneron Pharmaceuticals shares are worth, recalculated every trading day.
$1,298.15
Gekko Fair Value, Nov 4, 2026
28.3% Undervalued
At the end of Aug 2026 the price was 40.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open REGN in Gekko
Regeneron Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Regeneron Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in REGN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for REGN, plotted on the chart in Gekko.Open REGN in Gekko
Buybacks
Regeneron Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2026
- $399.7M
- As a share of market cap
- 0.42%
- Trailing four quarters
- $3.04B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds REGN.
1added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Regeneron Pharmaceuticals earnings: next date and track record
Regeneron Pharmaceuticals reports on Jan 28, 2027, before the open (84 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Jan 28, 2027
Expected before the open, 84 days away
- EPS estimate
- $25.30
- Revenue estimate
- $5.85B
7 of 8reports beat the EPS estimate
±7.1%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 30, 2026 AI summary
- What they said
- Regeneron reported Q3 2026 total revenue growth of 36% and non-GAAP EPS growth of 70% YoY, marking the third consecutive quarter of double-digit growth. Dupixent global net sales reached a record $6.5B (up 35% constant currency), with US sales hitting $5B for the first time. EYLEA HD US net sales grew 62% YoY to ~$700M, while Libtayo global net sales rose 51% to $550M, now on a ~$2.2B annual run rate.
- Guidance
- Management expects EYLEA HD prefilled syringe approval before year-end, anticipated to drive further adoption. Pipeline described as poised to deliver several potential blockbuster opportunities over the next several years. No specific EPS or revenue targets were provided in this excerpt.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 30, 2026 | $20.07 est $16.51 | $5.12B est $4.58B | +17.4% |
| Jul 30, 2026 | $12.53 est $8.00 | $4.29B est $3.82B | +9.7% |
| Apr 29, 2026 | $9.47 est $9.16 | $3.61B est $3.48B | −3.4% |
| Jan 30, 2026 | $11.44 est $10.52 | $3.88B est $3.81B | +0.7% |
| Oct 28, 2025 | $11.83 est $9.65 | $3.75B est $3.59B | +11.5% |
| Aug 1, 2025 | $12.89 est $8.43 | $3.68B est $3.29B | +4.8% |
| Apr 29, 2025 | $8.22 est $8.62 | $3.03B est $3.25B | −2.0% |
| Feb 4, 2025 | $12.07 est $11.21 | $3.79B est $3.74B | +7.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Regeneron Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Regeneron Pharmaceuticals is $969.59, +4.2% from the last close, from 24 firms rating the stock in the last 90 days.
$969.59consensus 12-month target, +4.2% from the last close
Now $930.67Avg $969.59
Low $770High $1,175
Each firm’s latest rating in the last 90 days: 24 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Morgan Stanley | $855 | −8.1% |
| Nov 2 | Robert W. Baird | $875 | −6.0% |
| Nov 2 | Guggenheim | $1,100 | +18.2% |
| Nov 2 | Cantor Fitzgerald | $980 | +5.3% |
| Nov 2 | Truist Financial | $982 | +5.5% |
+3.0%average 20-day move after past Distribution readings
+1.3%average move over the next 20 trading days in the last 5 years
±3.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Regeneron Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Regeneron Pharmaceuticals averaged +1.3% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.2% | 1 of 5 |
| Next 10 trading days | +1.1% | 2 of 5 |
| Next 15 trading days | +2.6% | 2 of 5 |
| Next 20 trading days | +1.3% | 3 of 5 |
| Next 30 trading days | +1.2% | 2 of 5 |
For scale, REGN’s typical 20-trading-day move in either direction is about 5%.
Regeneron Pharmaceuticals market cap and key statistics
Regeneron Pharmaceuticals’s market cap is $95.80B, with a P/E ratio of 21.3 and revenue of $16.90B over the last twelve months.
Valuation
- Market cap
- $95.80B
- P/E ratio
- 21.3
- Forward P/E
- 15.4
- EPS, TTM
- $45.24
- Gekko Fair Value
- $1,298.15
Trading
- Volume
- 1.38M
- Avg volume, 20 days
- 854,230
- 52-week high
- $991.73
- 52-week low
- $591.52
- Shares outstanding
- 101.6M
Financials
- Revenue, TTM
- $16.90B
- Profit margin
- 28.5%
- Return on equity
- 14.9%
- Quarterly earnings growth, YoY
- +35.5%
Risk and income
- Beta
- 0.10
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±5%
- Dividend yield
- 0.40%
Regeneron Pharmaceuticals stock news this week
Coverage of Regeneron Pharmaceuticals this week reads positive: 16 positive, 5 neutral and 1 negative headlines.
- Is Regeneron Stock Increasing Your Market Risk?Trefis, Nov 4
- 180 Regeneron (REGN) shares are proposed for sale by Stephanie Pitofsky.Stock Titan, Nov 4
- Form 4 Regeneron Pharmaceuticals Inc: Christine A. Poon (Director) For: 2 NovemberInvesting.com Canada, Nov 4
- Was There Any Sign Regeneron Stock Would Run?Trefis, Nov 4
- Eli Lilly, Regeneron Lead Weight-Loss ETF THNR HigherETF Database, Nov 4
- Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitorsMarketWatch, Nov 4
Regeneron Pharmaceuticals peers
Regeneron Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| JNJJohnson & Johnson | Neutral | 1.7% below |
| ABBVAbbVie | Neutral | 26.5% above |
| MRKMerck | Neutral | 8.6% below |
| AZNAstraZeneca | Distribution | 34.1% below |
| PFEPfizer | Neutral | 4.1% below |
A peer links to its own page where one exists.
Regeneron Pharmaceuticals stock FAQ
What is Regeneron Pharmaceuticals’s market cap?
Regeneron Pharmaceuticals’s market cap is $95.80B at the Nov 4, 2026 close of $930.67, with 101.6M shares outstanding. The shares trade on a P/E ratio of 21.3.
What is the Regeneron Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Regeneron Pharmaceuticals is $969.59, +4.2% from the last close. Of the 24 firms that rated the stock in the last 90 days, 16 rate it a buy, 8 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Regeneron Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Regeneron Pharmaceuticals is undervalued: the Nov 4, 2026 close of $930.67 is 28.3% below Gekko Fair Value of $1,298.15. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Regeneron Pharmaceuticals report earnings next?
Regeneron Pharmaceuticals is expected to report on Jan 28, 2027, before the market opens (84 days away). Analysts expect earnings of $25.30 per share on revenue of $5.85B. Regeneron Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 7.1% on average across the report.
What is Regeneron Pharmaceuticals’s 52-week high and low?
Regeneron Pharmaceuticals’s 52-week high is $991.73 and its 52-week low is $591.52; it closed at $930.67 on Nov 4, 2026, +44.9% over the past year. Over the last five years the shares peaked at $1,211.20 on Aug 27, 2024.
Is Regeneron Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality) and 1 as a headwind (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Regeneron Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.